Advertisement
Advertisement

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

COX-2 inhibitors and cardiovascular risk - Inferences based on biology and clinical studies

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Topic:

COX-2 inhibitors and the thrombotic risk

DOI: http://dx.doi.org/10.1160/TH06-07-0385
Issue: 2006: 96/4 (Oct) pp. 391-543
Pages: 401-406

COX-2 inhibitors and cardiovascular risk - Inferences based on biology and clinical studies

Muhammad R. Marwali, Jawahar L. Mehta

Cardiovascular Division, Department of Medicine, University of Arkansas for Medical Sciences, and the Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA

Keywords

Atherosclerosis, thrombosis, inflammation, hypercoagulability, coronary syndrome

Summary

Even though non-steroidal anti-inflammatory drugs (NSAIDs) have been widely used for a long time, the search continues for anti-inflammatory drugs with few side-effects. COX-2 inhibitors are currently most debated, because they have less gastrointestinal side effects but have been linked to increased cardiovascular morbidity and mortality, presumably related to thrombotic events.This has brought about the withdrawal of rofecoxib and other COX-2 inhibitors from the market. Although the results of several large studies with prospective, randomized design and meta-analysis of different trials have led to the demise of many popular COX-2 inhibitors, yet the conclusion seems to be rather simplistic.This review presents evidence from basic biology and clinical studies with the expectation that a balanced position, particularly in relation to increase in cardiovascular events, may be elucidated.

You may also be interested in...

1.

Online Supplementary Material

R. Suades (1, 2), T. Padró (1, 2), R. Alonso (3), P. Mata (3), L. Badimon (1, 2, 4)

Thromb Haemost 2013 110 2: 366-377

http://dx.doi.org/10.1160/TH13-03-0238

2.

L. Badimon (1, 2, 3), R. F. Storey (4), G. Vilahur (1, 2)

Thromb Haemost 2011 105 Suppl. 1: S34-S42

http://dx.doi.org/10.1160/THS10-11-0717

3.
Didier Hanriot1,2*, Gaëlle Bello1,2*, Armelle Ropars1,2, Carole Seguin-Devaux5, Gaël Poitevin1,2, Sandrine Grosjean3, Véronique Latger-Cannard2,3,4, Yvan Devaux1,2,5, Faiez Zannad1,2, Véronique Regnault2,4, Patrick Lacolley1,2, Paul-Michel Mertes1,2, Ketsia Hess*1,2, Dan Longrois*1,2

Thromb Haemost 2008 99 3: 558-569

http://dx.doi.org/10.1160/TH07-06-0410